- Home
- IVT vs DNLI Comparison
IVT vs DNLI Comparison
Compare IVT & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IVT
- DNLI
- Stock Information
- Founded
- IVT 2005
- DNLI 2013
- Country
- IVT United States
- DNLI United States
- Employees
- IVT N/A
- DNLI N/A
- Industry
- IVT Real Estate Investment Trusts
- DNLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IVT Real Estate
- DNLI Health Care
- Exchange
- IVT Nasdaq
- DNLI Nasdaq
- Market Cap
- IVT 2.2B
- DNLI 2.1B
- IPO Year
- IVT N/A
- DNLI 2017
- Fundamental
- Price
- IVT $29.98
- DNLI $15.43
- Analyst Decision
- IVT Buy
- DNLI Strong Buy
- Analyst Count
- IVT 5
- DNLI 15
- Target Price
- IVT $32.25
- DNLI $33.62
- AVG Volume (30 Days)
- IVT 374.2K
- DNLI 2.0M
- Earning Date
- IVT 10-28-2025
- DNLI 11-05-2025
- Dividend Yield
- IVT 3.18%
- DNLI N/A
- EPS Growth
- IVT 1533.99
- DNLI N/A
- EPS
- IVT 1.47
- DNLI N/A
- Revenue
- IVT $287,075,000.00
- DNLI N/A
- Revenue This Year
- IVT $9.93
- DNLI N/A
- Revenue Next Year
- IVT $8.00
- DNLI $802.87
- P/E Ratio
- IVT $20.31
- DNLI N/A
- Revenue Growth
- IVT 9.17
- DNLI N/A
- 52 Week Low
- IVT $25.21
- DNLI $10.57
- 52 Week High
- IVT $31.65
- DNLI $33.33
- Technical
- Relative Strength Index (RSI)
- IVT 69.45
- DNLI 56.61
- Support Level
- IVT $29.32
- DNLI $14.52
- Resistance Level
- IVT $30.03
- DNLI $16.20
- Average True Range (ATR)
- IVT 0.46
- DNLI 0.70
- MACD
- IVT 0.08
- DNLI -0.01
- Stochastic Oscillator
- IVT 82.74
- DNLI 62.44
About IVT InvenTrust Properties Corp.
InvenTrust Properties Corp is the United States of America based company qualified as a REIT (Real Estate Investment Trust). It is focused on owning, leasing, redeveloping, acquiring and managing a multi-tenant retail platform. The company's wholly-owned and managed retail properties include grocery-anchored community and neighborhood centers and power centers, including those classified as necessity-based. InvenTrust operates through a single segment i.e. multi-tenant retail.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.